Indeed, EET-A has previously been demonstrated to decrease renal inflammatory cell infiltration and levels of monocyte chemoattractant protein-1 (MCP-1), TNF-α, IL-6, and IL-1β in acute and chronic kidney disease models [11,12,26]. Here, IL1B is linked to chronic kidney disease.